Search Within

GDMT, Medicine

Formats
  1. Journal Article (929)
  2. Meeting Abstract (829)
  3. Review (49)
  4. Book Section (38)
  5. Editorial (29)
  6. Guidelines (19)
  7. Correspondence (7)
  8. Research Letter (1)
Groups
  1. Gynecology Disease Management Team (1901)
  2. Department of Medicine (1890)
  3. Solid Tumor Oncology Division (1890)
  4. Gynecologic Medicine Service (1850)
  5. Surgery (582)
  6. GDMT, Surgery (465)

More Groups

People
  1. Carol Aghajanian (613)
  2. Martee Hensley (290)
  3. Nadeem Abu-Rustum (279)
  4. Roisin O'Cearbhaill (272)
  5. Vicky Makker (267)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (64)
  2. 2024 (159)
  3. 2023 (165)
  4. 2022 (196)
  5. 2021 (146)
  6. 2020 (173)

More Years

Publications
  1. Journal of Clinical Oncology (418)
  2. Gynecologic Oncology (416)
  3. International Journal of Gynecological Cancer (152)
  4. Annals of Oncology (106)
  5. Clinical Cancer Research (64)
  6. Cancer (37)

More Publications

Publishers
  1. Elsevier Inc. (496)
  2. American Society of Clinical Oncology (450)
  3. Lippincott Williams & Wilkins (177)
  4. American Association for Cancer Research (139)
  5. Oxford University Press (128)
  6. Nature Publishing Group (73)

More Publishers

Results (1901)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Novel therapeutics in ovarian cancer: Expanding the toolbox
    Review

    Moufarrij, S.; O'Cearbhaill, R. E.
    Current Oncology (2023)

    Fulltext@MSK | Save
  • Real-world treatment patterns in recurrent or advanced endometrial cancer patients on first-line systemic therapy in the United States
    Meeting Abstract

    Ogando, Y. M.; Chen, L.; Zhang, J.; Kelkar, S. S.; Prabhu, V. S.; Miles, N.; Green, A.; Makker, V.
    Pharmacoepidemiology and Drug Safety (2023)

    Fulltext@MSK | Save
  • PRIMA/ENGOT-OV26/GOG-3012 study: Long-term conditional progression-free survival (cPFS)
    Meeting Abstract

    Braicu, E.; González-Martín, A.; Pothuri, B.; Vergote, I.; Graybill, W.; Mirza, M. R.; McCormick, C.; Lorusso, D.; Freyer, G.; Backes, F. J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • PD-1 blockade as curative intent therapy in mismatch repair deficient locally advanced rectal cancer
    Meeting Abstract

    Cercek, A.; Lumish, M.; Sinopoli, J.; Weiss, J.; Shia, J.; Stadler, Z.; Yaeger, R.; Smith, J. J.; Saltz, L.; Widmar, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
    Meeting Abstract

    Meric-Bernstam, F.; Makker, V.; Oaknin, A.; Oh, D. Y.; Banerjee, S.; Gonzalez Martin, A.; Jung, K. H.; Lugowska, I.; Manso, L. M.; Manzano, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/ paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
    Meeting Abstract

    Eskander, R. N.; Sill, M.; Miller, A.; Beffa, L.; Moore, R.; Hope, J.; Musa, F.; Mannel, R.; Shahin, M. S.; Canturia, G.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)
    Meeting Abstract

    Liu, J. F.; Brady, M.; Matulonis, U. A.; Miller, A.; Kohn, E. C.; Swisher, E.; Tew, W.; Cloven, N.; Muller, C.; Bender, D.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors
    Meeting Abstract

    McKean, M.; Dumbrava, E. E.; Hamid, O.; Merriam, P.; Call, J. A.; Feely, W.; Green, A.; Vaishampayan, U. N.; Moore, K. N.; Weroha, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)
    Meeting Abstract

    Shapiro, G. I.; Basu, B.; El-Khoueiry, A. B.; Postel-Vinay, S.; Im, S. A.; Rha, S. Y.; Friedman, C. F.; Italiano, A.; Kim, Y. M.; Lim, M. C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/ KEYNOTE-775
    Meeting Abstract

    Colomba, E.; Lorusso, D.; Mackay, H.; Moore, R.; Yonemori, K.; Kim, Y. M.; Sanli, U. A.; Xie, R.; Barresi, G.; McKenzie, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save